Renal sympathetic denervation in the aftermath of Symplicity HTN-3

Blood Pressure

Volumn 23, Issue 5, 2014, Pages 256-261

  Kjeldsen, Sverre E ^a   Fadl Elmula, Fadl E M ^a   Persu, Alexandre ^b,c   Jin, Yu ^d   Staessen, Jan A ^d,e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; HAWTHORNE EFFECT; HUMAN; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; RESISTANT HYPERTENSION; REVIEW; WHITE COAT HYPERTENSION; ATTITUDE TO HEALTH; BLOOD PRESSURE; HYPERTENSION; INNERVATION; KIDNEY; MEDICATION COMPLIANCE; MOTIVATION; OBSERVER VARIATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPATHECTOMY; TREATMENT OUTCOME;

BLOOD PRESSURE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; KIDNEY; MEDICATION ADHERENCE; MOTIVATION; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84907046784     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2014.953861     Document Type: Review

References (49)

1. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009;373: 1275-1281.
2. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010;376: 1903-1909.
3. Krum H, Schlaich MP, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-629.
4. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
5. Demaria AN. Reflections on renal denervation. J Am Coll Cardiol. 2014;63:1452-1453.
6. Von Euler US, Hellner S, Purkhold A. Excretion of noradrenaline in urine in hypertension. Scand J Clin Lab Invest. 1954; 6:54-59.
7. Julius S, Esler M. Autonomic nervous cardiovascular regulation in borderline hypertension. Am J Cardiol. 1975; 36:685-696.
8. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V. Agreement among three different indices of sympathetic nervous system activity in essential hypertension. Mayo Clin Proc. 1977;52:379-382.
9. Eide I, Kolloch R, DeQuattro V, Miano L, Dugger R, Van der Meulen J. Raised cerebrospinal fluid norepinephrine in some patients with primary hypertension. Hypertension. 1979;1:255-260.
10. Esler M, Jackman G, Leonard P, Bobik A, Skews H, Jennings G, et al. Determination of noradrenaline uptake, spillover to plasma and plasma concentration in patients with essential hypertension. Clin Sci (Lond). 1980;59 Suppl 6:311s-313s.
11. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension? Clin Sci (Lond). 1981;61 Suppl 7:215s-217s.
12. Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB, Julius S. Sympathetic nervous system involvement in essential hypertension: Increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness. Blood Press. 1994;3:164-171.
13. Gifford RW. An algorithm for the management of resistant hypertension. Hypertension. 1988;11:I-171-I-175.
14. Klein LE. Compliance and blood pressure control. Hypertension. 1988;11:I-161-I-164.
15. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87-90.
16. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
17. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359: 995-1003.
18. Julius S, Kjeldsen SE, Weber M, Brunner H, Ekman S, Hansson L, et al. Cardiac events, stroke and mortality in high-risk hypertensives treated with valsartan or amlodipine: Main outcomes of The VALUE Trial. Lancet. 2004;363: 2022-2031.
19. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: Insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: The CONVERGE report. Heart. 2013; 99:1579-1587.
20. Shun-Shin MJ, Howard JP, Francis DP. Removing the hype from hypertension. Symplicity HTN-3 illustrates the importance of randomisation and blinding for exciting new treatments. BMJ. 2014;348:g1937.
21. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013; 31:1731-1768.
22. Persu A, O'Brien E, Verdecchia P. Use of ambulatory blood pressure measurement in the definition of resistant hypertension: A review of the evidence. Hypertens Res. 2014 Apr 4. doi: 10.1038/hr.2014.83. [Epub ahead of print]
23. Kikuya M, Hansen TW, Thijs L, Bjrklund-Bodegârd K, Kuznetsova T, Ohkubo T, et al.; IDACO investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Press Monit. 2007;12:393-395.
24. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340-2346.
25. Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg. 2012;43:293-299.
26. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: Ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596-606.
27. Staessen JA, Thijs L, Bieniaszewski L, O'Brien ET, Palatini P, Davidson C, et al. Ambulatory monitoring uncor-rected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Hypertension. 1996;27:414-420.
28. Lüscher TF, Mahfoud F. Renal nerve ablation after Symplicity HTN-3: Confused at the higher level? Eur Heart J. 2014; 35:1706-1711.
29. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2013;62:450-452.
30. Fadl Elmula FEM, Hoffmann P, Fossum E, Brekke M, Gjonnss E, Hjornholm U, et al. Renal sympathetic denerva-tion in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526-532.
31. Persu A, Renkin J, Asayama K, O'Brien E, Staessen JA. Renal denervation in treatment-resistant hypertension: The need for restraint and more and better evidence. Expert Rev Cardiovasc Ther. 2013;11:739-749.
32. Persu A, Jin Y, Azizi M, Baelen M, Völz S, Elvan A, et al., on behalf of the European Network Coordinating research on REnal denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-156.
33. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Medicine. 1980: 69:725-732.
34. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: Prospective case series. Hypertension. 2012;60:1485-1490.
35. Fadl Elmula FEM, Hoffman P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to sympathetic renal denervation in patients with true treatment resistant hypertension. Hypertension. 2014;63:691-699.
36. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140.
37. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA,Veelken R, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880-1886.
38. Jin Y, Persu A, Staessen JA. Letter by Jin et al. regarding article, "Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension". Circulation. 2014;129:e499.
39. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: Renal denervation-An interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-841.
40. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. Updated ESH position paper on interventional therapy of resistant hypertension. Euro Intervention. 2013;9:R58-R66.
41. Schmieder RE. How should data from Symplicity HTN3 be interpreted? Nat Rev Cardiol. Advance online publication 20 May 2014; doi:10.1038/nrcardio.2014.70.
42. Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, et al. From Symplicity HTN-3 to the Renal Denervation Global Registry: Where do we stand and where should we go? Euro Intervention. 2014;10:21-23.
43. Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension; A review of 76 patients. Br J Surg. 1954;41:382-392.
44. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension, results in 1,266 cases. JAMA. 1953; 152:1501-1504.
45. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, et al.; European Network Coordinating research on REnal Denervation (ENCOReD) Consortium. Eligibility for renal denervation: Experience at 11 European expert centers. Hypertension. 2014;63:1319-1325.
46. Persu A Jin Y, Fadl Elmula FEM, Jacobs L, Renkin J, Kjeldsen SE. Renal denervation after Symplicity HTN-3: An update. Curr Hypertens Rep. 2014;16:460. DOI 10.1007/s11906-014-0460-x.
47. Oz M. Pressure relief. This year brings a breakthrough procedure to fight hypertension. Time Magazine. 2012, January 9, page 28.
48. Blech J. Vergebens verbrutzelt. Ein Eingriff an den Nierennerven gilt als neues Wundermittel gegen Bluthochdruck. Dabei ist nicht bewiesen, dass die Methode den Patienten wirklich nutzt. Der Spiegel. 2013, No. 28:102-103.
49. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with anti-hypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-245.